Evaluating combined bevacizumab and XELOX in advanced colorectal cancer: Serum markers carcinoembryonic antigen, carbohydrate antigen 125, carbohydrate antigen 199 analysis

Table 4 Levels of serum carcinoembryonic antigen, carbohydrate antigen 199, carbohydrate antigen 125 in the two groups

Group	CEA (μg/mL)		CA199 (U/mL)		CA125 (U/mL)
	Before treatment	After treatment	Before treatment	After treatment	Before treatment	After treatment
Observation group (n = 47)	8.22 ± 0.76	1.53 ± 0.12a	50.63 ± 4.75	20.67 ± 2.01a	72.90 ± 7.04	43.09 ± 5.63a
Control group (n = 47)	8.35 ± 0.71	3.91 ± 0.19a	51.22 ± 4.92	39.54 ± 2.76a	72.83 ± 7.12	45.13 ± 6.97a
χ2	0.857	72.607	0.591	37.889	0.038	2.247
P value	0.3197	< 0.001	0.278	< 0.001	0.97	0.0217

^aP < 0.05. Serum tumor marker levels of carcinoembryonic antigen, carbohydrate antigen (CA) 199 and CA125 in the control and observation groups. CEA: Carcinoembryonic antigen; CA: Carbohydrate antigen.